Navigation Links
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Date:1/16/2008

any's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:
-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the CEA, ACS and

FDG-PET clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

-- the results of our clinical trials, including without limitation, with

respect to the safety and ef
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
6. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Argentina Biomedical Sensors Market - Growth, Trends ... The Argentina Biomedical Sensors market is estimated ... 1.17% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical ... at a CAGR of 3.26% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:8/31/2015)... Mass. , Aug. 31, 2015  RXi ... company focused on discovering and developing innovative therapies ... today announced that the 30-day review period following ... (IND) for ocular indications with the U.S. Food ... IND is now active. Logo ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... 28, 2011 Qteros, Inc., the developer of a ... platform for the lowest-cost production of cellulosic ethanol, today ... throughout the month of May. Kevin A. ... for Qteros, will deliver an oral presentation at the ...
... 2011 Omnicare Clinical Research (CR), a leading global, ... has been acquired by Nautic Partners, LLC, a private ... the deal not only makes official the separation of Omnicare ... the company,s most visible step in a comprehensive two-year ...
... April 28, 2011 Reportlinker.com announces that ... in its catalogue: Case ... of biomarker identification and companion diagnostic co-development ... Introduction The ...
Cached Biology Technology:Qteros Management to Present at Upcoming Conferences in May 2Omnicare Clinical Research Acquired by Nautic Partners, LLC 2Omnicare Clinical Research Acquired by Nautic Partners, LLC 3Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 2Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 3
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/24/2015)... 24, 2015  Based on its recent analysis of the ... 2015 African Biometrics Company of the Year Award. DERMALOG is ... success in Africa . It has particularly ... has implemented one of the largest biometric mass applications in ... the Central Bank of Nigeria with ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... all terrorist attacks from 1970 to 2008 occurred in just ... rural areas, spurred on by domestic actors, according to a ... the Study of Terrorism and Responses to Terrorism (START), a ... based at the University of Maryland. The research was ...
... Nature Genetics today has found new evidence for ... 2 diabetes. The study found that people who carry rare ... higher risk of type 2 diabetes. The findings should ... could lead to the development of personalised treatments. Previous ...
... Nature Climate Change today finds that tropical vegetation ... Using a combination of remote sensing and field data, scientists ... University of Maryland were able to produce the first "wall-to-wall" ... m) of carbon storage of forests, shrublands, and savannas in ...
Cached Biology News:5 US urban counties lead 'Terror Hot Spots' list, but rural areas not exempt 25 US urban counties lead 'Terror Hot Spots' list, but rural areas not exempt 3Body clock receptor linked to diabetes in new genetic study 2The good news about carbon storage in tropical vegetation 2The good news about carbon storage in tropical vegetation 3
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
Biology Products: